BARDA to Fund $1B to AstraZeneca for Research and Development of Novel COVID-19 Vaccines

 BARDA to Fund $1B to AstraZeneca for Research and Development of Novel COVID-19 Vaccines

AstraZeneca’s Lokelma Receives CHMP’s Recommendation for Approval for Patients with Hyperkalemia on Stable Hemodialysis

Shots:

  • The $1B support is for the development, production and delivery of the vaccine with its initiation in H2’20 including a P-III trial with 30,000 participants and a pediatric trial.AZ has initiated to provide wider access to University of Oxford’s vaccine and concluded to provide 400M doses has secured total manufacturing capacity for 1B doses with its deliveries in Sep 2020
  • AZ is in contract with CEPI, Gavi the Vaccine Alliance, WHO for allocation and distribution of vaccine globally and with some of the governments for increasing access. Additionally, AZ has also collaborated with Serum Institute of India and other partners for increase in production and distribution. AZ has finalized its agreement with Oxford University for vaccine, (formerly ChAdOx1 nCoV-19) and now AZD1222, following the global development and distribution agreement with University’s Jenner Institute and the Oxford Vaccine Group
  • In Apr 2020, the P-I/II was initiated which involved the assessing AZD1222 in 1,000 healthy volunteers aged 18 to 55 yrs. in several centers in southern England. The company has also initiated trials to assess Calquence (acalabrutinib) in CALAVI and ACCORD trials while Farxiga (dapagliflozin) in DARE-19 trial for COVID-19 patients

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Pharma world

Related news: Johnson & Johnson and BARDA to Fund ~$1B in Research and Development of Novel COVID-19 Vaccines

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post